Research. Advocacy. Support.
We advance ovarian cancer research while supporting women and their families.
Know Your Risks
About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.
(March 28, 2017) The U.S. Food and Drug Administration approved niraparib (ZEJULA, TESARO, Inc.), poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib is the first PARP inhibitor to be approved… More
(March 23, 2017) OCRFA staff and volunteers recently attended the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer, held March 11-14, 2017 in Maryland. Every year women’s cancer physicians and researchers gather at this meeting to discuss the latest in the care and treatment of women with ovarian and other gynecologic cancers. OCRFA… More
(March 15, 2017) Results from a large study showed that screening for ovarian cancer in high-risk patients led to detection of significantly more early-stage disease as compared with the year after screening ended. However, it is not yet known whether this screening approach would improve survival in screened high-risk women. The results of the study… More
Join us for an evening of laugh-out-loud stand up performances, a raucous live auction, and cocktail...May 15 @ 6:00 pm - 8:30 pm EDT
This is truly a can’t miss event—join us in Chicago for a weekend of hope, inspirat...July 7 @ 8:00 am - July 9 @ 5:00 pm EDT
OCRFA’s Super Saturday is a daylong shopping event that brings top luxury name brands in high ...July 29 @ 8:00 am - 5:00 pm EDT